Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Valero-Hernandez Ester, Mathur Jai, Baker David, Liu Iris Y H, Morgan Sarah L, Tallantyre Emma C, Schmierer Klaus, Kang Angray S
Аннотация
BACKGROUND: Natalizumab is a high-efficacy therapy drug for multiple sclerosis that inhibits lymphocyte migration into the central nervous system, increasing lymphocyte counts in the peripheral blood. Anti-drug antibody responses may limit drug efficacy, but current guidance recommends anti-drug antibody testing only after evidence of 'reduced efficacy'.
OBJECTIVE: To assess the lack of relative lymphocytosis as a biomarker of anti-drug antibody responses.
METHODS: Lymphocyte counts and immunogenicity data from the pivotal AFFIRM clinical trial (n = 627 natalizumab vs n = 315 placebo) and real-world data from the Cardiff MS register (n = 185) were analysed to assess the relationship between lymphocyte counts, anti-drug antibody responses, drug levels and disease activity.
RESULTS: Natalizumab treatment induced an absolute change in lymphocyte counts by week 12 (1.40 ± 0.92 vs -0.05 ± 0.62 × 109 cells/L in natalizumab vs placebo; p < 0.0001) that was absent in the persistent anti-drug antibody group (-0.12 ± 0.60 × 109 cells/L). Increases in lymphocyte counts by ⩾ 0.8 × 109 cells/L from the baseline discriminated individuals without anti-drug antibody responses with high sensitivity (≥ 84%) and specificity (≥ 91%).
CONCLUSION: The absence of relative lymphocytosis is associated with anti-drug antibody responses and may provide a simple biomarker to prompt anti-drug antibody testing before disease breakthrough occurs.
OBJECTIVE: To assess the lack of relative lymphocytosis as a biomarker of anti-drug antibody responses.
METHODS: Lymphocyte counts and immunogenicity data from the pivotal AFFIRM clinical trial (n = 627 natalizumab vs n = 315 placebo) and real-world data from the Cardiff MS register (n = 185) were analysed to assess the relationship between lymphocyte counts, anti-drug antibody responses, drug levels and disease activity.
RESULTS: Natalizumab treatment induced an absolute change in lymphocyte counts by week 12 (1.40 ± 0.92 vs -0.05 ± 0.62 × 109 cells/L in natalizumab vs placebo; p < 0.0001) that was absent in the persistent anti-drug antibody group (-0.12 ± 0.60 × 109 cells/L). Increases in lymphocyte counts by ⩾ 0.8 × 109 cells/L from the baseline discriminated individuals without anti-drug antibody responses with high sensitivity (≥ 84%) and specificity (≥ 91%).
CONCLUSION: The absence of relative lymphocytosis is associated with anti-drug antibody responses and may provide a simple biomarker to prompt anti-drug antibody testing before disease breakthrough occurs.